Urology SACT regimens:
Whilst every effort is made to ensure the accuracy of the information in a given regimen it cannot be guaranteed that the regimen is fully up to date, because of the dynamic nature of cancer treatment. Check the regimen details for the specific indication the regimen may be used / funded in. See our disclaimer.
Thames Valley have agreed that an H2 antagonist is no longer required as premedication before paclitaxel doses.
Therefore H2 antagonist premedication may be omitted from paclitaxel regimens.
Paclitaxel and cabazitaxel may be administered via a DEHP free line instead of the polyethylene lined giving set specified in the regimens.
Bladder
- Atezolizumab
- Avelumab
- Enfortumab vedotin Pembrolizumab
- Erdafitinib
- Gemcitabine with concurrent RT
- Gemcitabine Carboplatin
- Gemcitabine Cisplatin
- Mitomycin Fluorouracil with concurrent RT
- MVAC accelerated
- Paclitaxel (weekly for 3 weeks then 1 week off)
- Paclitaxel Carboplatin
Germ cell tumour or seminoma
- BEP 3 day adjuvant
- BEP 3 day metastatic
- BEP 5 day metastatic
- Carboplatin
- Carboplatin (AUC 10) (Local funding)
- EP
- Irinotecan Paclitaxel Oxaliplatin (IPO)
- Paclitaxel Etoposide Cisplatin (PEC)
- Paclitaxel Ifosfamide Cisplatin (TIP) (5 day)
Penile
Prostate
- Abiraterone Prednisolone
- Apalutamide
- Cabazitaxel (Blueteq registration no longer required)
- Darolutamide
- Darolutamide Docetaxel Prednisolone
- Docetaxel Prednisolone
- Docetaxel weekly Prednisolone
- Enzalutamide
- Olaparib
- Olaparib Abiraterone Prednisolone
Renal
- Avelumab Axitinib
- Axitinib
- Cabozantinib
- Cabozantinib Nivolumab
- Everolimus (Blueteq registration no longer required)
- Everolimus Lenvatinib
- Lenvatinib Pembrolizumab
- Ipilimumab Nivolumab
- Nivolumab
- Pazopanib
- Pembrolizumab
- Sunitinib
- Tivozanib
Urothelial
Cisplatin hydration
Bladder installations
SACT regimens written by S Coutts
For further information please contact us using our contact us page.